Array BioPharma Giving Back Gains Seen In Advance of ARRY-797 Data

Array BioPHarma (NASDAQ:ARRY) announced that its novel treatment for pain, ARRY-797, met its primary endpoint in a Phase 2 clinical trial, however, safety issues are clouding the good news. The 157-patient trial tested the drug in patients suffering from osteoarthritis of the knee with moderate to severe pain. Results demonstrated a statistically significant relief in pain vs. placebo, and similar pain reduction to the narcotic pain treatment, Oxycontin. The hope is that this novel p38 inhibitor can offer pain relief similar to the most potent drugs, with fewer side effects that are commonly seen with narcotics.